152 related articles for article (PubMed ID: 8976822)
1. Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
Budd GT; Ganapathi R; Bukowski RM; Murthy S
Eur J Cancer; 1996; 32A Suppl 4():S43-5. PubMed ID: 8976822
[TBL] [Abstract][Full Text] [Related]
2. Amifostine and chemotherapy-related thrombocytopenia.
Budd GT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):49-52. PubMed ID: 8783667
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors.
Budd GT; Ganapathi R; Adelstein DJ; Pelley R; Olencki T; Petrus J; McLain D; Zhang J; Capizzi R; Bukowski RM
Cancer; 1997 Sep; 80(6):1134-40. PubMed ID: 9305715
[TBL] [Abstract][Full Text] [Related]
4. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
[TBL] [Abstract][Full Text] [Related]
5. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin.
Borsi JD; Csaki C; Ferencz T; Oster W
Anticancer Drugs; 1996 Jan; 7(1):121-6. PubMed ID: 8742109
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of WR-2721 and carboplatin.
Budd GT; Ganapathi R; Bauer L; Murthy S; Adelstein D; Weick J; Gibson V; McLain D; Sergi J; Bukowski RM
Eur J Cancer; 1993; 29A(8):1122-7. PubMed ID: 8390844
[TBL] [Abstract][Full Text] [Related]
8. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
Korst AE; van der Sterre ML; Eeltink CM; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
Clin Cancer Res; 1997 May; 3(5):697-703. PubMed ID: 9815738
[TBL] [Abstract][Full Text] [Related]
10. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
11. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
Lorusso D; Ferrandina G; Greggi S; Gadducci A; Pignata S; Tateo S; Biamonte R; Manzione L; Di Vagno G; Ferrau' F; Scambia G;
Ann Oncol; 2003 Jul; 14(7):1086-93. PubMed ID: 12853351
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
[TBL] [Abstract][Full Text] [Related]
14. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
15. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
16. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
Schuchter LM
Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
[TBL] [Abstract][Full Text] [Related]
17. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Fulda S; Fichtner I; Hero B; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):199-202. PubMed ID: 11464883
[TBL] [Abstract][Full Text] [Related]
19. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
20. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
